

RESULT 1

AAM40223

ID AAM40223 standard; Protein; 229 AA.

XX

AC AAM40223;

XX

DT 22-OCT-2001 (first entry)

XX

DE Human polypeptide SEQ ID NO 3368.

XX

KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;  
KW peripheral nervous system; neuropathy; central nervous system; CNS;  
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;  
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;  
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;  
KW leukaemia.

XX

OS Homo sapiens.

XX

PN WO200153312-A1.

XX

PD 26-JUL-2001.

XX

PF 26-DEC-2000; 2000WO-US34263.

XX

PR 21-JAN-2000; 2000US-0488725.

PR 25-APR-2000; 2000US-0552317.

PR 09-JUL-2000; 2000US-0598042.

PR 19-JUL-2000; 2000US-0620312.

PR 03-AUG-2000; 2000US-0653450.

PR 14-SEP-2000; 2000US-0662191.

PR 19-OCT-2000; 2000US-0693036.

PR 29-NOV-2000; 2000US-0727344.

XX

PA (HYSE-) HYSEQ INC.

XX

PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;

PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;

PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;

XX

DR WPI; 2001-442253/47.

DR N-PSDB; AAI59379.

XX

PT Novel nucleic acids and polypeptides, useful for treating disorders  
PT such as central nervous system injuries -

XX

PS Example 5; SEQ ID NO 3368; 10078pp; English.

XX

CC The invention relates to human nucleic acids (AAI57798-AAI61369) and  
CC the encoded polypeptides (AAM38642-AAM42213) with nootropic,  
CC immunosuppressant and cytostatic activity. The polynucleotides are useful  
CC in gene therapy. A composition containing a polypeptide or polynucleotide  
CC of the invention may be used to treat diseases of the peripheral nervous  
CC system, such as peripheral nervous injuries, peripheral neuropathy and  
CC localised neuropathies and central nervous system diseases, such as  
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic  
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the  
CC utilisation of the activities such as: Immune system suppression,  
CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic  
CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,  
CC assays for receptor activity, arthritis and inflammation, leukaemias and  
CC C.N.S disorders.  
CC Note: The sequence data for this patent did not form part of the printed  
CC specification.

XX

SQ Sequence 229 AA;

Query Match 100.0%; Score 1198; DB 22; Length 229;

Best Local Similarity 100.0%; Pred. No. 2.5e-127;

Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	MAAQPLRHRSRCATPPRGDFCGGTERAIDQASFTTSMEDWTQVVKGSSPLGPAGLGAEPP	60
Db	1	MAAQPLRHRSRCATPPRGDFCGGTERAIDQASFTTSMEDWTQVVKGSSPLGPAGLGAEPP	60
Qy	61	AAGPOLPSWLQPERCAVFOCAQCHAVLADSVHLAWDLRSRLGAVVFSRVNTNNVLEAPFL	120
Db	61	AAGPOLPSWLQPERCAVFOCAQCHAVLADSVHLAWDLRSRLGAVVFSRVNTNNVLEAPFL	120
Qy	121	VGIEGSLKGSTYNLLFCGSCGIPVGFHLYSTHAALALRGHFCLSSDKMVCYLLKTKAIV	180
Db	121	VGIEGSLKGSTYNLLFCGSCGIPVGFHLYSTHAALALRGHFCLSSDKMVCYLLKTKAIV	180
Qy	181	NASEMDIQNVPLSEKIAELKEKIVLTHNRLKSLMKILSEVTPDQSKPEN	229
Db	181	NASEMDIQNVPLSEKIAELKEKIVLTHNRLKSLMKILSEVTPDQSKPEN	229

XX	Sequence	231 AA;
XX	Query Match	100.0%; Score 1198; DB 22; Length 231;
XX	Best Local Similarity	100.0%; Pred. No. 2.5e-127;
XX	Matches	229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	1	MAAOPLRHRSRCATPPRGDFCGGTERAIDQASFTTSMEMDQOVVKGSSPLGAGAEAP 60
DB	3	MAAOPLRHRSRCATPPRGDFCGGTERAIDQASFTTSMEMDQOVVKGSSPLGAGAEAP 62
QY	61	AAGPOLPSWLOPERCAVRCQAQCAHVLADSVHLANDLSRSLGAVVPSRVYNNVLEAPPL 120
DB	63	AAGPOLPSWLOPERCAVRCQAQCEAVLADSVHLANDLSRSLGAVVPSRVYNNVLEAPPL 122
QY	121	VGIEGSLKSTYNTLFCGSCGIPVGFHLYSTHAAALALRGHCTSSDRKVCYLTKKAIY 180
DB	123	VGIEGSLKSTYNTLFCGSCGIPVGFHLYSTHAAALALRGHCTSSDRKVCYLTKKAIY 182
QY	181	NASEMDIQNVPLSEKIAELKEKIVLTNRNLKSIKILSEVTPDQSKPEN 229
DB	183	NASEMDIQNVPLSEKIAELKEKIVLTNRNLKSIKILSEVTPDQSKPEN 231

RESULT 3  
 ID AAM42009 standard; Protein; 231 AA.  
 AC AAM42009;  
 CX 22-OCT-2001 (first entry)  
 CX Human polypeptide SEQ ID NO 6940.  
 CX Human; nocrotropic; immunosuppressant; cytostatic; gene therapy; cancer;  
 CX peripheral nervous system; neuropathy; central nervous system; CNS;  
 CX Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;  
 CX amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;  
 CX chemoketic; thrombolytic; drug screening; arthritis; inflammation;  
 CX leukaemia.  
 CX Homo sapiens.  
 CX MO20015312-A1.  
 CX 26-JUL-2001.  
 CX 26-DEC-2000; 2000MO-US34263.  
 CX 21-JAN-2000; 2000US-0488725.  
 CX 25-APR-2000; 2000US-0552317.  
 CX 09-JUL-2000; 2000US-0598042.  
 CX 19-JUL-2000; 2000US-0620312.  
 CX 03-AUG-2000; 2000US-0653450.  
 CX 14-SEP-2000; 2000US-0662191.  
 CX 19-OCT-2000; 2000US-0693036.  
 CX 29-NOV-2000; 2000US-0727344.  
 CX (HYSE-) HYSEQ INC.  
 CX Tang YF, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;  
 CX Wang J, Wang Z, Wenman T, Xu C, Xue AJ, Yang Y, Zhang J;  
 CX Zhao QH, Zhou P, Goodrich R, Drmanac RT;  
 CX WPI; 2001-442253/47.  
 CX N-PSDB; AAI61165.  
 CX Novel nucleic acids and polypeptides, useful for treating disorders  
 CX such as central nervous system injuries -  
 CX Example 2; SEQ ID NO 6940; 10078bp; English.  
 CX The invention relates to human nucleic acids (AA157798-AA161369) and  
 CX the encoded polypeptides (AAM38642-AAM4213) with nocrotropic;  
 CX immunosuppressant and cytostatic activity. The polynucleotides are useful  
 CX in gene therapy. A composition containing a polypeptide or polynucleotide  
 CX of the invention may be used to treat diseases of the peripheral nervous  
 CX system, such as peripheral nervous injuries, peripheral neuropathy and  
 CX localised neuropathies and central nervous system diseases, such as  
 CX Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic  
 CX lateral sclerosis, and Shy-Drager Syndrome. Other uses include the  
 CX utilisation of the activities such as: Immune system suppression,  
 CX Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic  
 CX and thrombolytic activity, cancer diagnosis and therapy, drug screening,  
 CX assays for receptor activity, arthritis and inflammation, leukaemias and  
 CX C.N.S disorders.  
 CX Note: The sequence data for this patent did not form part of the printed  
 CX specification.